Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 152

1.

Lixisenatide reduces chylomicron triacylglycerol due to increased clearance.

Whyte MB, Shojaee-Moradie F, Sharaf SE, Jackson NC, Fielding B, Hovorka R, Mendis J, Russell-Jones D, Umpleby AM.

J Clin Endocrinol Metab. 2018 Sep 11. doi: 10.1210/jc.2018-01176. [Epub ahead of print]

PMID:
30215735
2.

Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study.

Otowa-Suematsu N, Sakaguchi K, Nakamura T, Hara K, Kishi M, Hashimoto N, Yokota K, Yoshino H, Kuroki Y, Nishiumi T, Sou A, Komada H, Okada Y, Hirota Y, Tamori Y, Ogawa W.

Diabetes Ther. 2018 Sep 11. doi: 10.1007/s13300-018-0505-2. [Epub ahead of print]

PMID:
30206903
3.

Lixisenatide requires a functional gut-vagus nerve-brain axis to trigger insulin secretion in controls and type 2 diabetic mice.

Charpentier J, Waget A, Klopp P, Magnan C, Cruciani-Guglielmacci C, Lee SJ, Burcelin R, Grasset E.

Am J Physiol Gastrointest Liver Physiol. 2018 Aug 2. doi: 10.1152/ajpgi.00348.2017. [Epub ahead of print]

PMID:
30070580
4.

Lixisenatide.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

5.

Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.

Rosenstock J, Handelsman Y, Vidal J, Ampudia Blasco FJ, Giorgino F, Liu M, Perfetti R, Meier JJ.

Diabetes Obes Metab. 2018 Jul 4. doi: 10.1111/dom.13462. [Epub ahead of print]

PMID:
29974618
6.
7.

Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone.

Trujillo JM, Roberts M, Dex T, Chao J, White J, LaSalle J.

Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13444. [Epub ahead of print]

PMID:
29923298
8.

Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients.

Tonneijck L, Muskiet MHA, Twisk JW, Kramer MHH, Danser AHJ, Joles JA, Smits MM, van Raalte DH.

Hypertension. 2018 Aug;72(2):314-322. doi: 10.1161/HYPERTENSIONAHA.117.10740. Epub 2018 Jun 18.

PMID:
29915021
9.

Lixisenatide ameliorates cerebral ischemia-reperfusion injury via GLP-1 receptor dependent/independent pathways.

Abdel-Latif RG, Heeba GH, Taye A, Khalifa MMA.

Eur J Pharmacol. 2018 Aug 15;833:145-154. doi: 10.1016/j.ejphar.2018.05.045. Epub 2018 Jun 1.

PMID:
29864411
10.
11.

More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L.

Frias J, Puig Domingo M, Meneghini L, Napoli R, Liu M, Soltes Rak E, Aroda VR.

Diabetes Obes Metab. 2018 Sep;20(9):2314-2318. doi: 10.1111/dom.13368. Epub 2018 Jun 13.

12.
14.

Lixisenatide, a novel GLP-1 analog, protects against cerebral ischemia/reperfusion injury in diabetic rats.

Abdel-Latif RG, Heeba GH, Taye A, Khalifa MMA.

Naunyn Schmiedebergs Arch Pharmacol. 2018 Jul;391(7):705-717. doi: 10.1007/s00210-018-1497-1. Epub 2018 Apr 18.

PMID:
29671019
15.

The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study.

Božek T, Bilić-Ćurčić I, Berković MC, Gradišer M, Kurir TT, Majanović SK, Marušić S.

Diabetol Metab Syndr. 2018 Mar 13;10:16. doi: 10.1186/s13098-018-0321-x. eCollection 2018.

16.

Methodological concerns with the meta-analysis comparing insulin degludec/liraglutide and insulin glargine/lixisenatide.

Eggert S, Zimmermann E, Begtrup K.

Expert Opin Pharmacother. 2018 Mar;19(4):317-318. doi: 10.1080/14656566.2018.1444882. Epub 2018 Mar 5. No abstract available.

PMID:
29471700
17.

Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes.

Ericsson Å, Glah D, Lorenzi M, Jansen JP, Fridhammar A.

PLoS One. 2018 Feb 6;13(2):e0191953. doi: 10.1371/journal.pone.0191953. eCollection 2018.

18.

Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease.

Cai HY, Yang JT, Wang ZJ, Zhang J, Yang W, Wu MN, Qi JS.

Biochem Biophys Res Commun. 2018 Jan 1;495(1):1034-1040. doi: 10.1016/j.bbrc.2017.11.114. Epub 2017 Nov 22.

PMID:
29175324
19.

An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin.

Evans M, Billings LK, Håkan-Bloch J, Slothuus U, Abrahamsen TJ, Andersen A, Jansen JP.

J Med Econ. 2018 Apr;21(4):340-347. doi: 10.1080/13696998.2017.1409228. Epub 2017 Dec 3.

PMID:
29164973
20.

Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis.

Cai X, Gao X, Yang W, Ji L.

Expert Opin Pharmacother. 2017 Dec;18(17):1789-1798. doi: 10.1080/14656566.2017.1400011. Epub 2017 Nov 5. Review.

PMID:
29090600

Supplemental Content

Loading ...
Support Center